MBRX - Moleculin Biotech, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
0.7850
-0.0161 (-2.01%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
MACD

MACD

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close0.8011
Open0.8217
Bid0.0000 x 1300
Ask0.8900 x 1800
Day's Range0.7800 - 0.8217
52 Week Range0.3230 - 1.9700
Volume833,314
Avg. Volume2,128,206
Market Cap47.417M
Beta (5Y Monthly)2.40
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
All
News
Press Releases
  • Moleculin Provides Update on Annamycin Clinical Development
    PR Newswire

    Moleculin Provides Update on Annamycin Clinical Development

    Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced an update on its clinical development plan for Annamycin.

  • New Publication Finds Combination of WP1066 and Radiation Resulted in Long-Term Survival in Human Brain Tumor Mouse Model
    PR Newswire

    New Publication Finds Combination of WP1066 and Radiation Resulted in Long-Term Survival in Human Brain Tumor Mouse Model

    Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that a peer-reviewed article published in Clinical Cancer Research (Clin Cancer Res June 30 2020 DOI:10.1158/1078-0432.CCR-19-4092) reported findings that Moleculin's STAT3 inhibitor, WP1066, used in combination with traditional whole brain radiation therapy (WBRT) resulted in long-term survivors and enhanced median survival time relative to monotherapy in mice with implanted human brain tumors.

  • ACCESSWIRE

    INVESTIGATION ALERT: Fields Kupka & Shukurov LLP Is Investigating Moleculin Biotech, Inc. for Potential Breach of Fiduciary Duty Claims

    NEW YORK, NY / ACCESSWIRE / June 30, 2020 / Fields Kupka & Shukurov LLP is investigating potential breach of fiduciary duty claims involving the board of directors of Moleculin Biotech, Inc. (NASDAQ: MBRX ...

  • GlobeNewswire

    Life Sciences Companies Investor Presentations Now Available for On-Demand Viewing

    NEW YORK, June 29, 2020 -- Life Sciences Investor Forum today announced that the presentations from the June 25th conference are now available for on-demand viewing at.

  • Moleculin Announces Preclinical Data Confirms Efficacy of Annamycin in Lung Metastases
    PR Newswire

    Moleculin Announces Preclinical Data Confirms Efficacy of Annamycin in Lung Metastases

    Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced a presentation at the American Association of Cancer Research (AACR) Annual Meeting held from June 22nd-24th, 2020, illustrating a unique approach to creating drugs capable of reaching tumors hiding in organs where existing anticancer drugs cannot accumulate in therapeutic concentrations. A poster presentation entitled, "Targeting Cancer Sanctuary Sites: A Novel Approach to the Treatment of Lung Localized Tumors," provided an overview of data demonstrating that uniquely high uptake and retention of Annamycin in the lungs results in consistently high in vivo activity against wide range of lung-localized tumors in mice.

  • GlobeNewswire

    Virtual Conference for Life Sciences Companies Broadcast Live June 25, 2020

    NEW YORK, June 23, 2020 -- Life Sciences Investor Forum today announced the agenda for its second quarterly event for public and private companies, investors and industry.

  • Moleculin to Present at the Life Sciences Investor Forum
    PR Newswire

    Moleculin to Present at the Life Sciences Investor Forum

    Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced that Walter Klemp, Chairman and Chief Executive Officer, will present at the Life Sciences Investor Forum being held virtually on June 25th, 2020 at 1:30pm ET.

  • Moleculin Announces Confirmatory In Vitro Analysis of WP1122
    PR Newswire

    Moleculin Announces Confirmatory In Vitro Analysis of WP1122

    Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates, today announced that a repeat of previous in vitro testing has corroborated the antiviral potential of WP1122.

  • Moleculin Announces Submission to Expand Clinical Sites in European AML Trial
    PR Newswire

    Moleculin Announces Submission to Expand Clinical Sites in European AML Trial

    Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates, today announced that it has submitted requests to Polish regulatory authorities for approval to open two additional clinical sites for its Phase 1/2 clinical study of Annamycin for the treatment of acute myeloid leukemia ("AML").

  • Moleculin Announces Emory University Clinical Trial of WP1066 Begins Enrollment
    PR Newswire

    Moleculin Announces Emory University Clinical Trial of WP1066 Begins Enrollment

    Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates, today announced that recruiting has begun and the first patient has been enrolled in the Emory University Phase 1 clinical trial of WP1066 for the treatment of brain tumors in children. The study is being conducted at the Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta.

  • Moleculin Announces Common Stock Will Resume Trading on the NASDAQ on May 28, 2020
    PR Newswire

    Moleculin Announces Common Stock Will Resume Trading on the NASDAQ on May 28, 2020

    Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that it has received notification from Nasdaq that trading in the Company's common stock will resume on Thursday, May 28, 2020.

  • GlobeNewswire

    Nasdaq Scheduled Resumption in Moleculin Biotech, Inc.

    NEW YORK, May 27, 2020 -- The Nasdaq Stock Market® (Nasdaq: NDAQ) announced that trading in Moleculin Biotech, Inc. (Nasdaq: MBRX) is scheduled to resume on Thursday, May 28,.

  • Moleculin Provides Update on Coronavirus Drug Development
    PR Newswire

    Moleculin Provides Update on Coronavirus Drug Development

    Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that the US Food and Drug Administration ("FDA") has granted the Company's request for a Pre-IND Meeting to provide guidance regarding the Company's plan to study its drug candidate, WP1122, in a clinical trial for patients with COVID-19 (the disease caused by the SARS-CoV-2 coronavirus). In addition, Moleculin provided a general update on its WP1122 development efforts.

  • GlobeNewswire

    Nasdaq Halts Moleculin Biotech Inc.

    NEW YORK, May 18, 2020 -- The Nasdaq Stock Market® (Nasdaq: NDAQ) announced that the trading halt status in Moleculin Biotech Inc. (Nasdaq: MBRX) was changed to "additional.

  • Moleculin Announces Nasdaq Trading Halt Pending Receipt of Additional Information
    PR Newswire

    Moleculin Announces Nasdaq Trading Halt Pending Receipt of Additional Information

    Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that pending the receipt of additional information from the Company, Nasdaq has halted the trading in the Company's common stock. The Company is actively working with the staff of Nasdaq to provide it with all requested information, and hopes to begin trading as soon as possible.

  • Moleculin Provides Additional Comments Regarding Trading Halt
    PR Newswire

    Moleculin Provides Additional Comments Regarding Trading Halt

    Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that since the May 1st, 2020 temporary suspension by the Securities and Exchange Commission (SEC) of trading in the securities of Moleculin Biotech, Inc. (MBRX), additional information has come to the Company's attention regarding claims disseminated by third parties.

  • Investor Alert: Kaplan Fox Investigates Moleculin Biotech, Inc.
    PR Newswire

    Investor Alert: Kaplan Fox Investigates Moleculin Biotech, Inc.

    Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of Moleculin Biotech, Inc. ("Moleculin" or the "Company") (NASDAQ: MBRX). Investors who purchased Moleculin securities may be affected.

  • Moleculin Announces Intention to Adjourn 2020 Annual Meeting of Stockholders to June 15, 2020
    PR Newswire

    Moleculin Announces Intention to Adjourn 2020 Annual Meeting of Stockholders to June 15, 2020

    Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced its intention to adjourn its 2020 Annual Meeting of Stockholders.

  • Moleculin Announces Trading Halt
    PR Newswire

    Moleculin Announces Trading Halt

    Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced securities of the Company have been placed in a temporary trading halt following notification by the US Securities and Exchange Commission.

  • Moleculin to Speak on COVID-19 Panel at Maxim Group's Infectious Disease Virtual Conference
    PR Newswire

    Moleculin to Speak on COVID-19 Panel at Maxim Group's Infectious Disease Virtual Conference

    Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced that Walter Klemp, Chairman and Chief Executive Officer, will participate on the COVID-19 panel at Maxim Group's Infectious Disease Virtual Conference on May 5th from 3:45 p.m. ET to 5:00 p.m. ET. To RSVP for the virtual conference, please click through: Maxim Group's Infectious Disease Virtual Conference.

  • GlobeNewswire

    WPD Pharmaceutical’s Annamycin Drug Approved for Accelerated European Clinical Trial

    VANCOUVER, British Columbia, April 29, 2020 -- WPD Pharmaceuticals Inc. (CSE: WBIO) (FSE: 8SV1) (the “Company” or “WPD”) a clinical stage pharmaceutical company is pleased to.

  • Moleculin Approved to Accelerate European Clinical Trial
    PR Newswire

    Moleculin Approved to Accelerate European Clinical Trial

    Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates, today announced that it is now authorized by the Polish Department of Registration of Medicinal Products known as URPL to accelerate the Phase 1 dose escalation portion of its clinical trial of Annamycin for the treatment of acute myeloid leukemia (AML).

  • GlobeNewswire

    WPD Pharmaceuticals’ Annamycin Drug Candidate Meets Endpoint in Successful U.S. Phase 1 AML Trial With No Evidence of Cardiotoxicity

    WPD Pharmaceuticals Inc. (CSE:WBIO) (8SV1.F) (the “Company” or “WPD”) a clinical stage pharmaceutical company is pleased to provide an update on its Annamycin drug candidate. The phase 1 trial met its objective of demonstrating the safety of Annamycin.

  • Moleculin Announces Head of NIAID Antiviral Drug Discovery and Development Center Joins COVID-19 Drug Development Team
    PR Newswire

    Moleculin Announces Head of NIAID Antiviral Drug Discovery and Development Center Joins COVID-19 Drug Development Team

    Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates, today announced that it has welcomed Dr. Richard Whitley to its Science Advisory Board to guide its development strategy for WP1122 for the potential treatment of COVID-19 and other viral diseases.

  • GlobeNewswire

    WPD Pharmaceuticals and CNS Pharmaceuticals Announce Additional Coronavirus Testing on WP1122 by ImQuest Biosciences

    VANCOUVER, British Columbia, April 21, 2020 -- WPD Pharmaceuticals Inc. (CSE: WBIO) (FSE: 8SV1) (the “Company” or “WPD”) a clinical stage pharmaceutical company along with its.